{
  "slug": "guardant-health",
  "name": "Guardant Health",
  "description": "Guardant Health is a leading precision oncology company focused on helping conquer cancer globally through use of its proprietary blood tests, vast data sets, and advanced analytics. The company specializes in liquid biopsy technology to provide genomic insights across all stages of the cancer care continuum, from screening to therapy selection and recurrence monitoring.",
  "url": "https://optimly.ai/brand/guardant-health",
  "logoUrl": "",
  "baiScore": 88,
  "archetype": "Challenger",
  "category": "Biotechnology",
  "categorySlug": null,
  "keyFacts": [],
  "aiReadiness": [],
  "competitors": [
    {
      "slug": "natera",
      "name": "Natera"
    }
  ],
  "inboundCompetitors": [
    {
      "slug": "foundation-medicine",
      "name": "Foundation Medicine"
    },
    {
      "slug": "illumina-grail",
      "name": "GRAIL"
    },
    {
      "slug": "invitae-invitae",
      "name": "Invitae Invitae"
    },
    {
      "slug": "adaptive-biotechnologies",
      "name": "Adaptive Biotechnologies"
    },
    {
      "slug": "delfi-diagnostics",
      "name": "Delfi Diagnostics"
    }
  ],
  "aiAlternatives": [],
  "parentBrand": {
    "slug": "independent-publicly-traded",
    "name": "Independent Publicly Traded"
  },
  "subBrands": [],
  "updatedAt": "2026-04-10T07:30:57.552+00:00",
  "verifiedVitals": {
    "website": "https://www.guardanthealth.com",
    "founded": "2012",
    "headquarters": "Palo Alto, California, USA",
    "pricing_model": "Insurance-billed medical diagnostic with patient assistance programs; typical of clinical laboratory services.",
    "core_products": "Guardant360, Guardant Reveal, Shield, GuardantOMNI",
    "key_differentiator": "The first company to achieve FDA approval for a comprehensive liquid biopsy and for a blood-based colorectal cancer screening test for average-risk adults.",
    "target_markets": "Oncologists, health systems, biopharmaceutical companies, and primary care physicians.",
    "employee_count": "1,000-2,000",
    "funding_stage": "Public (NASDAQ: GH)",
    "subcategory": "Precision Oncology & Liquid Biopsy"
  },
  "intentTags": {
    "problemIntents": [
      "Traditional Tissue Biopsy: Using traditional tissue-based biopsies requiring invasive surgical procedures to collect tumor samples.",
      "Standard Screening Protocols: Adhering to standard-of-care screening protocols (like colonoscopies) without supplemental molecular insights."
    ],
    "solutionIntents": [
      "best liquid biopsy for lung cancer therapy selection",
      "FDA approved blood test for colorectal cancer screening",
      "ctDNA testing for cancer recurrence monitoring",
      "comprehensive genomic profiling companies",
      "Standard Medical Imaging: Monitoring cancer progression through standard diagnostic imaging such as CT scans, MRIs, or PET scans."
    ],
    "evaluationIntents": [
      "how does guardant reveal compare to signatera"
    ]
  },
  "timestamp": 1777190473545
}